Mass Balance Study of MT-1303
NCT02293967
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
8
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
DRUG:
MT-1303
Sponsor
Tanabe Pharma Corporation